Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics
Nymox Pharmaceutical Corporation (NYMX)
Today's Latest Price: $2.24 USD
Updated Dec 4 4:00pm
Add NYMX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NYMX Stock Summary
- With a price/sales ratio of 1,178.79, Nymox Pharmaceutical Corp has a higher such ratio than 99.42% of stocks in our set.
- With a year-over-year growth in debt of -84.21%, Nymox Pharmaceutical Corp's debt growth rate surpasses merely 2.71% of about US stocks.
- As for revenue growth, note that NYMX's revenue has grown -59.1% over the past 12 months; that beats the revenue growth of just 3.67% of US companies in our set.
- Stocks that are quantitatively similar to NYMX, based on their financial statements, market capitalization, and price volatility, are CRNX, ARNA, MRTX, CBMG, and CVM.
- Visit NYMX's SEC page to see the company's official filings. To visit the company's web site, go to www.nymox.com.
NYMX Stock Price Chart Interactive Chart >
NYMX Price/Volume Stats
| Current price | $2.24 | 52-week high | $4.79 |
| Prev. close | $1.92 | 52-week low | $1.66 |
| Day low | $1.92 | Volume | 202,600 |
| Day high | $2.25 | Avg. volume | 197,569 |
| 50-day MA | $2.17 | Dividend yield | N/A |
| 200-day MA | $2.74 | Market Cap | 172.95M |
Nymox Pharmaceutical Corporation (NYMX) Company Bio
Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.
Loading social stream, please wait...